SLAS Discovery - Special Issue on Advances in MALDI Mass Spectrometry for Drug Discovery - Volume 22 Issue 10 - December 2017 - 1210

1210
For many secondary screens, CE-based assays are our
preferred orthogonal readout, which generate high-quality
data for the validation of hit series from primary screens.
These primary screens typically run with assay technologies, which generates more biased hit series.8 Therefore, we
choose our internal gold standard21 for the evaluation of
MALDI-MS-based assay and process development. We are
extremely impressed by the power of MALDI-MS and the
opportunity to integrate MALDI-MS systems, like a standard reader, in our ultra-HTS workflow using acoustic
transfer for target preparation. Besides the high-quality
data, the label-free assay technology, and the expansion of
target space, it allows us to eliminate the necessity to run
orthogonal assays. Here we identified a big chance for early
drug discovery departments that have to deal with the
reduction of cycle times and the pressure to deliver first-inclass molecules for innovative target classes.
Acknowledgment
We thank Meike Hamester, Volker Sauerland, Franz J. Mayer, and
Jens Fuchser from Bruker Daltonics (Bremen, Germany) for their
valuable input and helpful discussions.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article: No
funding for this work was received by the authors. All research
was done as work-for-hire for the employer Merck KGaA.

References
1. Macarron, R. Critical Review of the Role of HTS in Drug
Discovery. Drug Discov. Today 2006, 11, 277-279.
2. Greis, K. D. Mass Spectrometry for Enzyme Assays
and Inhibitor Screening: An Emerging Application in
Pharmaceutical Research. Mass Spectrom. Rev. 2007, 26,
324-339.
3. Haslam, C.; Hellicar, J.; Dunn, A.; et al. The Evolution
of MALDI-TOF Mass Spectrometry toward Ultra-HighThroughput Screening: 1536-Well Format and Beyond. J.
Biomol. Screen. 2016, 21,176-186.
4. Thorne, N.; Auld, D. S.; Inglese, J. Apparent Activity in HighThroughput Screening: Origins of Compound-Dependent Assay
Interference. Curr. Opin. Chem. Biol. 2010, 14, 315-324.
5. Quercia, A. K.; LaMarr, W. A.; Myung, J.; et al. High-Throughput
Screening by Mass Spectrometry: Comparison with the
Scintillation Proximity Assay with a Focused-File Screen of
AKT1/PKB Alpha. J. Biomol. Screen. 2007, 12, 473-480.

SLAS Discovery 22(10)
6. De Boer, A. R.; Lingeman, H.; Niessen, W. M.; et al. Mass
Spectroscopy Based Biochemical Assays for EnzymeInhibitor Screening. Trends Anal. Chem. 2007, 26, 867-883.
7. Shiau, A. K.; Massari, M. E.; Özbal, C. C. Back to Basics:
Label-Free Technologies for Small Molecule Screening.
Comb. Chem. High Throughput Screen. 2008, 11, 231-237.
8. Simeonov, A.; Jadhav, J.; Thomas, C. J.; et al. Fluorescence
Spectroscopic Profiling of Compound Libraries. J. Med.
Chem. 2008, 51, 2363-2371.
9. Greis, K. D.; Zhou, S.; Burt, T. M.; et al. MALDI-TOF MS as
a Label-Free Approach to Rapid Inhibitor Screening. J. Am.
Soc. Mass. Spectrom. 2006, 17, 815-822.
10. Rathore, R.; Corr, J.; Scott, G.; et al. Development of an
Inhibitor Screening Platform via Mass Spectrometry. J.
Biomol. Screen. 2008, 13, 1007-1013.
11. Chandler, J.; Haslam, C.; Hardy, N.; et al. A Systematic
Investigation of the Best Buffers for Use in Screening by
MALDI-Mass Spectrometry. J. Biomol. Screen. 2016,
December 8.
12. Leveridge, M.; Buxton, R.; Argyrou, A.; et al. Demonstrating
Enhanced Throughput of RapidFire Mass Spectrometry
through Multiplexing Using the JmjD2d Demethylase as a
Model System. J. Biomol. Screen. 2014, 19, 278-286.
13. Yang, M.; Brazier, M.; Edwards, R.; et al. High-Throughput
Mass-Spectrometry Monitoring for Multisubstrate Enzymes:
Determining the Kinetic Parameters and Catalytic Activities
of Glycosyltransferases. ChemBioChem 2005, 6, 346-357.
14. Rathore, R.; Pribil, P.; Corr, J.; et al. Multiplex Enzyme
Assays and Inhibitor Screening by Mass Spectrometry. J.
Biomol. Screen. 2010, 15, 1001-1007.
15. Maegley, K. A.; Krivacic, C.; Bingham, P. Comparison of a
High-Throughput Mass Spectrometry Method and Radioactive
Filter Binding to Assay the Protein Methyltransferase
PRMT5. Assay Drug Dev. Technol. 2015, 13, 235-240.
16. Annesley, T. M. Ion Suppression in Mass Spectrometry. Clin.
Chem. 2003, 49, 1041-1044.
17. Liao, P. C.; Leykam, J.; Andrews, P. C. An Approach to
Locate Phosphorylation Sites in a Phosphoprotein: Mass
Mapping by Combining Specific Enzymatic Degradation
with Matrix-Assisted Laser Desorption/Ionization Mass
Spectrometry. Anal. Biochem. 1994, 219, 9-20.
18. Asara, J. M.; Allison, J. Enhanced Detection of Phosphopeptides
in Matrix-Assisted Laser Desorption/Ionization Mass
Spectrometry Using Ammonium Salts. J. Am. Soc. Mass
Spectrom. 1999, 10, 35-44.
19. Wingfield, J.; Wilson, I. D. Advances in Mass Spectrometry
within Drug Discovery. J. Biomol. Screening 2016, 21, 109-
110.
20. Aerni, H. R.; Cornett, D. S.; Caprioli, R. M. Automated
Acoustic Matrix Deposition for MALDI Sample Preparation.
Anal. Chem. 2006, 78, 827-834.
21. Perrin, D.; Fremaux, C.; Shutes, A. Capillary Microfluidic
Electrophoretic Mobility Shift Assays: Application to
Enzymatic Assays in Drug Discovery. Exp. Opin. Drug.
Discov. 2010, 5, 51-63.
Table of Contents for the Digital Edition of SLAS Discovery - Special Issue on Advances in MALDI Mass Spectrometry for Drug Discovery - Volume 22 Issue 10 - December 2017
